Stay updated on IV ABBV-383 Combo in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the IV ABBV-383 Combo in Multiple Myeloma Clinical Trial page.

Latest updates to the IV ABBV-383 Combo in Multiple Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe date has been updated from March 3, 2025, to March 4, 2025.SummaryDifference0.3%
- Check23 days agoChange DetectedThe date has been updated from February 6, 2025, to March 3, 2025.SummaryDifference0.6%
- Check30 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check45 days agoChange DetectedThe page now includes a notice about heavy traffic affecting NLM-NCBI services and products, along with a new date of February 6, 2025, while the previous date of January 27, 2025, has been removed.SummaryDifference6%
- Check52 days agoChange DetectedThe website has been updated to version 2.14.2 on January 27, 2025, following the removal of version 2.14.1 on January 15, 2025.SummaryDifference0.6%
- Check66 days agoChange DetectedA new study (v2.14.1) has been added to assess the effects of IV infused Etentamig (ABBV-383) in treating relapsed/refractory multiple myeloma, replacing the previous version (v2.14.0) that focused on ABBV-383.SummaryDifference2%
Stay in the know with updates to IV ABBV-383 Combo in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IV ABBV-383 Combo in Multiple Myeloma Clinical Trial page.